
Obesity drug competition expected to intensify by 2030
Viking Therapeutics’ dual GLP-1/GIP receptor agonist VK2735 could become a direct competitor to Eli Lilly’s Mounjaro/Zepbound (tirzepatide), predicts data analytics company GlobalData. In February 2024, Viking Therapeutics published Phase IIa results for its VK2735 candidate, which is being investigated both as a weekly subcutaneous… Read More








